CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. THE REDACTED TERMS HAVE BEEN MARKED WITH THREE ASTERISKS [***] LICENSE...License Agreement • October 10th, 2023 • First Wave BioPharma, Inc. • Pharmaceutical preparations
This License Agreement (this “Agreement”) is made and entered into as of September 12, 2023 (the “Effective Date”) by and between Sanofi, a French corporation, having offices at 46 avenue de la Grande Armée 75017 Paris FRANCE (“Sanofi” or “Licensor”) and First Wave BioPharma, Inc., a Delaware corporation, having offices located at 777 Yamato Road, Suite 502, Boca Raton, FL 33431, USA (“Licensee”). Sanofi and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
